Prof. Wu Yilong, MD, PhD
Founder of Guangdong Lung Cancer Institute · Past President of CSCO · IASLC Cullen Awardee | Guangdong Provincial People's Hospital (GDPH)
Prof. Wu Yilong, MD, PhD
Guangdong Provincial People's Hospital (GDPH)
-
Hospital AffiliationGuangdong Provincial People's Hospital (GDPH)
-
Clinical SpecialtyThoracic Medical Oncology, Targeted Therapy & EGFR Resistance
-
Clinical LanguagesEnglish, Mandarin, Cantonese
-
Clinical Experience40+ Years
-
Consultation Turnaround24–48 Hours Priority Review
World Luminary in Targeted Therapy and Molecular Resistance in Lung Cancer
Prof. Wu Yilong, MD, PhD, is Tenured Director of the Guangdong Lung Cancer Institute (GLCI) at Guangdong Provincial People's Hospital, Past President of the Chinese Society of Clinical Oncology (CSCO), and Founder of the Chinese Thoracic Oncology Group (CTONG). Globally recognized as a titan in thoracic oncology, he received the prestigious Joseph W. Cullen Prevention/Early Detection Award from the International Association for the Study of Lung Cancer (IASLC).
Prof. Wu's seminal research fundamentally reshaped how non-small cell lung cancer (NSCLC) is diagnosed and treated worldwide. As principal investigator of pivotal global trials—including AURA3, ADAURA, FLAURA, and CTONG-1104—he proved the curative potential of adjuvant osimertinib in resected EGFR-mutated NSCLC and established targeted therapies as the unquestioned first-line standard of care.
Leading Asia's foremost precision oncology laboratory, Prof. Wu specializes in resolving complex molecular resistance pathways (e.g. EGFR T790M, C797S, MET amplification, HER2 mutations, and RET/ROS1 fusions). His clinic provides international patients access to cutting-edge antibody-drug conjugates (ADCs), bispecific antibodies, and customized combination protocols that sustain long-term survival in advanced disease.
Procedural Frontiers & Department Innovations
Landmark ADAURA Adjuvant Targeted Protocol
Led the global phase III trial demonstrating an 80% reduction in disease recurrence with adjuvant osimertinib in stage IB-IIIA EGFR-mutated NSCLC.
Overcoming Complex EGFR Resistance
World leader in managing post-3rd generation TKI resistance through MET inhibitor combinations, HER3 ADCs, and customized dual-targeted regimens.
Perioperative Neoadjuvant Immunotherapy
Pioneered chemo-immunotherapy induction before surgery, raising major pathologic response (MPR) rates to >60% in resectable stage II/III lung cancer.
Circulating Tumor DNA (ctDNA) Dynamics
Translating ultra-deep liquid biopsy tracking into clinical decisions: identifying molecular relapse months before radiologic progression.
Distinguished National & International Recognition
CASE INTAKE & TARGETED THERAPY TRIAGE
Request a Thoracic Oncology Review with Prof. Wu Yilong, MD, PhD
Submit recent next-generation sequencing (NGS) molecular panels, lung biopsy histopathology reports, contrast chest CT & brain MRI DICOM scans, and a chronological history of prior targeted/immunotherapy drugs for direct triage by Prof. Wu Yilong. Our medical team responds within 24–48 hours.